The randomized phase III EMERALD trial enrolled patients with ER-positive, HER2-negative advanced breast cancer who had one or two lines of endocrine therapy, required pre-treatment with a cyclin-dependent kinase 4/6 inhibitor, and had one or no lines of chemotherapy. Here, ERBB2 is linked to breast cancer.